Only in Titles

           Search results for: Receptor   

paperclip

#28655027   2017/06/27 Save this To Up

Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review.

Given its selective action on the ω1 subtype of the γ-aminobutyric acid A receptor, zolpidem tartrate presents a potential treatment mechanism for other neurologic disorders.

2888 related Products with: Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review.

MOUSE ANTI BOVINE ROTAVIR Bone Morphogenetic Protei Growth Differentiation Fa Amplite™ Fluorimetric F MOUSE ANTI BORRELIA BURGD succinate-CoA ligase, GDP TCP-1 theta antibody Sour formin-like 1 antibody So succinate-CoA ligase, ADP Primary antibody Caspase Primary antibody FLIP An Glucose Assay With the La

Related Pathways

paperclip

#28654915   2017/06/27 Save this To Up

Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical challenges to cancer treatment. VS-4718 and VS-6063 are potent inhibitors of focal adhesion kinase (FAK), a non-receptor tyrosine kinase that mediates cell signals transmitted by integrins and growth factor receptors. We report here that inhibition of FAK kinase activity by VS-4718 or VS-6063 preferentially targets CSCs, as demonstrated by a panel of orthogonal CSC assays in cell line models and surgically resected primary breast tumor specimens cultured ex vivo. Oral administration of VS-4718 or VS-6063 to mice bearing xenograft models of triple-negative breast cancer (TNBC) significantly reduced the proportion of CSCs in the tumors, as evidenced by a reduced tumor-initiating capability upon re-implantation in limiting dilutions of cells prepared from these tumors. In contrast, the cytotoxic chemotherapeutic agents, paclitaxel and carboplatin, enriched for CSCs, consistent with previous reports that these cytotoxic agents preferentially target non-CSCs. Importantly, VS-4718 and VS-6063 attenuated the chemotherapy-induced enrichment of CSCs in vitro and delayed tumor regrowth following cessation of chemotherapy. An intriguing crosstalk between FAK and the Wnt/β-catenin pathway was revealed wherein FAK inhibition blocks β-catenin activation by reducing tyrosine 654 phosphorylation of β-catenin. Furthermore, a constitutively active mutant form of β-catenin reversed the preferential targeting of CSCs by FAK inhibition, suggesting that this targeting is mediated, at least in part, through attenuating β-catenin activation. The preferential targeting of cancer stem cells by FAK inhibitors provides a rationale for the clinical development of FAK inhibitors aimed to increase durable responses for cancer patients.

2193 related Products with: Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Macrophage Colony Stimula Macrophage Colony Stimula Dog Receptor-binding canc EnzyChrom™ Kinase Assay Stemez hN2 Human Neuron D Mouse Anti-Lipoprotein Li PKA (Protein Kinase A) Ac KinaseSTAR JNK Activity S KinaseSTAR JNK Activity A KinaseSTAR Akt Activity A Pyruvate Kinase Activity MarkerGeneTM in vivo lacZ

Related Pathways

paperclip

#28654905   2017/06/27 Save this To Up

MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor.

MicroRNAs (miRNAs) are dysregulated in cancers, including human non-small cell lung cancer (NSCLC). The function of MicroRNA-107-5p (miR-107-5p) in NSCLC is not fully elucidated. Epidermal growth factor receptor (EGFR) is a cancer-driven gene in tumorigenesis. In this study, we found that miR-107-5p was significantly decreased in NSCLC tissues and NSCLC cell lines. Moreover, our results indicated that miR-107-5p could suppress cell proliferation, inhibit metastasis, impede cell cycle, and promote apoptosis via directly targeting EGFR. We also investigated roles of miR-107-5p in vivo. The results showed that it could inhibit tumor growth. Therefore, our study demonstrated that miR-107-5p not only suppressed the progression in NSCLC cells by inhibiting the expression of EGFR, but also could be a promising and a new potential therapeutic target for lung cancer.

1254 related Products with: MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor.

Epidermal Growth Factor ( Epidermal Growth Factor ( Lung non small cell cance Non-small cell lung cance Epidermal Growth Factor ( Epidermal Growth Factor ( TCGF (Natural T Cell Grow CELLKINES PLATELET DERIVE CELLKINES PLATELET DERIVE Human Epidermal Growth Fa RABBIT ANTI HUMAN SDF-1 A Mouse Epidermal Growth Fa

Related Pathways

paperclip

#28654894   2017/06/27 Save this To Up

Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Ovarian cancer is the deadliest of all gynecologic cancers. Despite success with initial chemotherapy, the majority of patients relapse with an incurable disease. Development of chemotherapy resistance is a major factor for poor long-term survival in ovarian cancer. The biological effects of estrogens are mediated by estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). Emerging evidence suggests that ovarian cancer cells express ERβ that functions as a tumor suppressor; however, the clinical utility of ERβ agonists in ovarian cancer remains elusive. We tested the utility of two natural ERβ agonists liquiritigenin (Liq), which is isolated from Glycyrrhiza uralensis and S-equol, which is isolated from soy isoflavone daidzein, for treating ovarian cancer. Both natural ERβ ligands had significant growth inhibition in cell viability and survival assays, reduced migration and invasion, and promoted apoptosis. Further, ERβ agonists showed tumor suppressive functions in therapy-resistant ovarian cancer model cells and sensitized ovarian cancer cells to cisplatin and paclitaxel treatment. Global RNA-Seq analysis revealed that ERβ agonists modulate several tumor suppressive pathways, including downregulation of the NF-κB pathway. Immunoprecipitation assays revealed that ERβ interacts with p65 subunit of NF-κB and ERβ overexpression reduced the expression of NF-κB target genes. In xenograft assays, ERβ agonists reduced tumor growth and promoted apoptosis. Collectively, our findings demonstrated that natural ERβ agonists have the potential to significantly inhibit ovarian cancer cell growth by anti-inflammatory and pro-apoptotic actions, and natural ERβ agonists represent novel therapeutic agents for the management of ovarian cancer.

2845 related Products with: Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Mouse Anti-Human Estrogen Mouse Anti-Human Estrogen Mouse Anti-Human Estrogen Mouse Anti-Human Estrogen Mouse Anti-Human Estrogen Estrogen Receptor; Clone Estrogen Receptor; Clone CA125, Ovarian Cancer An CA125, Ovarian Cancer An Estrogen Receptor; Clone CA125, Ovarian Cancer An Estrogen Receptor á (Pho

Related Pathways

paperclip

#28654888   2017/06/27 Save this To Up

MEK inhibition enhances efficacy of bacillus Calmette-Guérin on bladder cancer cells by reducing release of toll-like receptor 2-activated antimicrobial peptides.

Bacillus Calmette-Guérin (BCG) is one of the standard treatment options for non-muscle-invasive bladder cancer. The details of the biological defense mechanisms against BCG remain unclear. Here, we investigated whether BCG-induced release of antimicrobial peptides (AMPs; e.g., human β-defensin-2, -3, and cathelicidin) is involved with mitogen-activated protein kinase (MAPK) pathways, and investigated the enhanced anticancer effect of BCG through the down-regulation of Toll-like receptors (TLRs) and MAPK pathways in bladder cancer cells. BCG-infected bladder cancer cells produced AMPs as a defense mechanism against BCG, which were reduced by MEK inhibitors by blocking phosphorylation of extracellular signal-regulated kinase (ERK1/2 or MEK) and c-Jun. MEK inhibitors enhanced inhibition of bladder cancer cell growth by decreased binding of c-Jun, p65 and Pol II to the activated protein-1 promoter. Knockdown of TLR2 and TLR4 reduced ERK phosphorylation. Knockdown of TLR 2 decreased release of AMPs, which was similar to the efficacy of MEK inhibitor on BCG-infected cells. BCG-infected bladder cancer cells were more prone to induction of AMP release following TLR2 activation via ERK and c-Jun pathway mediators. In conclusion, our data suggest that the BCG-induced release of AMPs in bladder cancer cells is a promising molecular target for enhancing the immunotherapeutic efficacy of BCG in bladder cancer patients.

1963 related Products with: MEK inhibition enhances efficacy of bacillus Calmette-Guérin on bladder cancer cells by reducing release of toll-like receptor 2-activated antimicrobial peptides.

anti Transferrin receptor Dog Receptor-binding canc Rat Toll Like Receptor 2( Rat Toll Like Receptor 6( anti CD38 Hematopoietic p Bladder cancer tissue arr Bladder cancer tissue arr Bladder cancer and normal Bladder cancer tissue arr Mid advanced stage bladde Tissue microarray of blad Bladder cancer high densi

Related Pathways

paperclip

#28654878   2017/06/27 Save this To Up

Development of a semi-quantitative risk assessment model for evaluating environmental threat posed by the three first EU watch-list pharmaceuticals to urban wastewater treatment plants: An Irish case study.

Contamination of receiving waters with pharmaceutical compounds is of pressing concern. This constitutes the first study to report on the development of a semi-quantitative risk assessment (RA) model for evaluating the environmental threat posed by three EU watch list pharmaceutical compounds namely, diclofenac, 17-beta-estradiol and 17-alpha-ethinylestradiol, to aquatic ecosystems using Irish data as a case study. This RA model adopts the Irish Environmental Protection Agency Source-Pathway-Receptor concept to define relevant parameters for calculating low, medium or high risk score for each agglomeration of wastewater treatment plant (WWTP), which include catchment, treatments, operational and management factors. This RA model may potentially be used on a national scale to (i) identify WWTPs that pose a particular risk as regards releasing disproportionally high levels of these pharmaceutical compounds, and (ii) help identify priority locations for introducing or upgrading control measures (e.g. tertiary treatment, source reduction). To assess risks for these substances of emerging concern, the model was applied to 16 urban WWTPs located in different regions in Ireland that were scored for the three different compounds and ranked as low, medium or high risk. As a validation proxy, this case study used limited monitoring data recorded at some these plants receiving waters. It is envisaged that this semi-quantitative RA approach may aid other EU countries investigate and screen for potential risks where limited measured or predicted environmental pollutant concentrations and/or hydrological data are available. This model is semi-quantitative, as other factors such as influence of climate change and drug usage or prescription data will need to be considered in a future point for estimating and predicting risks.

2417 related Products with: Development of a semi-quantitative risk assessment model for evaluating environmental threat posed by the three first EU watch-list pharmaceuticals to urban wastewater treatment plants: An Irish case study.

Analysis Tool for Custom Analysis Tool for Custom FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Normal rat multiple organ Normal rat multiple organ Normal rat multiple organ Multiple organ cancer tis Multiple organ tumor tiss

Related Pathways

paperclip

#28654867   2017/06/27 Save this To Up

Cholesterol-rich lipid rafts play a critical role in bovine parainfluenza virus type 3 (BPIV3) infection.

Lipid rafts are specialized lipid domains enriched in cholesterol and sphingolipid, which can be utilized in the lifecycle of numerous enveloped viruses. Bovine parainfluenza virustype3 (BPIV3) entry to cell is mediated by receptor binding and membrane fusion, but how lipid rafts in host cell membrane and BPIV3 envelope affect virus infection remains unclear. In this study, we investigated the role of lipid rafts in the different stages of BPIV3 infection. The MDBK cells were treated by methyl-β-cyclodextrin (MβCD) to disrupt cellular lipid raft, and the virus infection was determined. The results showed that MβCD significantly inhibited BPIV3 infection in a dose-dependent manner, but didn't block the binding of virus to the cell membrane. Whereas, the MDBK cells treated by MβCD after virus-entry had no effects on the virus infection, to suggest that BPIV3 infection was associated with lipid rafts in cell membrane during viral entry stage. To further confirm lipid rafts in viral envelope also affected BPIV3 infection, we treated BPIV3 with MβCD to determine the virus titer. We found that disruption of the viral lipid raft caused a significant reduction of viral yield. Cholesterol reconstitution experiment showed that BPIV3 infection was successfully restored by cholesterol supplementation both in cellular membrane and viral envelope, which demonstrated that cholesterol-rich lipid rafts played a critical role in BPIV3 infection. These findings provide insights on our understanding of the mechanism of BPIV3 infection and imply that lipid raft might be a good potential therapeutic target to prevent virus infection.

2240 related Products with: Cholesterol-rich lipid rafts play a critical role in bovine parainfluenza virus type 3 (BPIV3) infection.

Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Native Parainfluenza Viru Anti beta3 AR Human, Poly Human anti-parainfluenza Human Anti-Parainfluenza

Related Pathways

  •  
  • No related Items
paperclip

#28654861   2017/06/27 Save this To Up

Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier.

Decreased clearance of potentially toxic metabolites, due to aging changes, likely plays a significant role in the accumulation of amyloid-beta (Aβ) peptides and other macromolecules in the brain of the elderly and in the patients with Alzheimer's disease (AD). Aging is the single most important risk factor for AD development. Aβ transport receptor proteins expressed at the blood-brain barrier are significantly altered with age: the efflux transporters lipoprotein receptor-related protein 1 and P-glycoprotein are reduced, whereas the influx transporter receptor for advanced glycation end products is increased. These receptors play an important role in maintaining brain biochemical homeostasis. We now report that, in a rat model of aging, gene transcription is altered in aging, as measured by Aβ receptor gene messenger RNA (mRNA) at 3, 6, 9, 12, 15, 20, 30, and 36 months. Gene mRNA expression from isolated cerebral microvessels was measured by quantitative polymerase chain reaction. Lipoprotein receptor-related protein 1 and P-glycoprotein mRNA were significantly reduced in aging, and receptor for advanced glycation end products was increased, in parallel with the changes seen in receptor protein expression. Transcriptional changes appear to play a role in aging alterations in blood-brain barrier receptor expression and Aβ accumulation.

2833 related Products with: Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier.

Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Anti 3 DG imidazolone Mon pCAMBIA1301 Vector (gusA pCAMBIA2300 Vector (No Re pCAMBIA2301 Vector (gusA Amyloid Stain Kit (Congo Amyloid Stain Kit (Congo ATF3 Amyloid P component (seru

Related Pathways

  •  
  • No related Items
paperclip

#28654857   2017/06/27 Save this To Up

Long-term outcome of a 26-year-old woman with West syndrome and an nuclear receptor subfamily 2 group F member 1 gene (NR2F1) mutation.

Long-term outcome of West syndrome with a NR2F1 mutation.

2036 related Products with: Long-term outcome of a 26-year-old woman with West syndrome and an nuclear receptor subfamily 2 group F member 1 gene (NR2F1) mutation.

CAR,Car,Constitutive andr CAR,CAR,Constitutive acti CAR,Car,Constitutive andr G protein-coupled recepto Goat Anti- FPRL1 (aa13-26 RABBIT ANTI GSK3 BETA (pS RANK Ligand Soluble, Huma killer cell lectin-like r Primary antibody IL-1RAc Primary antibody IL-1RAc anti GFP antibody, rat mo IGF-1R Signaling Phospho-

Related Pathways

paperclip

#28654793   2017/06/27 Save this To Up

Pure total flavonoids from citrus improve non-alcoholic fatty liver disease by regulating TLR/CCL signaling pathway: A preliminary high-throughput 'omics' study.

This study investigated the possible molecular mechanisms of pure total flavonoids from citrus (PTFC) for the treatment of non-alcoholic fatty liver disease (NAFLD) via toll-like receptor/C-C chemokine ligand (TLR/CCL) signaling pathways by monitoring the changes in gene expression profile in liver tissues induced by high-fat diet.

2991 related Products with: Pure total flavonoids from citrus improve non-alcoholic fatty liver disease by regulating TLR/CCL signaling pathway: A preliminary high-throughput 'omics' study.

ENZYMATIC ASSAY KITS (CH LIVER DISEASES Total Bile LIVER DISEASES Total Bile HIV 1 gag p24 recombinant Anti HIV 1 p24 Clone 39 5 MONOBODIES (Monoclonal An Anti HIV 1 p24 Clone 39 5 MONOBODIES (Monoclonal An Hh Signaling Pathway Anta YKL-39 antibody Source Ra AP-1 Reporter – HEK293 Acedoben-d3 C9H5D3NO3 CAS

Related Pathways